{
  "docId": "019de074-a9ac-701c-b608-a7d685a23a86",
  "docSlug": "61bfab17df32945e4c5e1e9eb8b915b7",
  "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 22,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide highlights the mechanism of action (sweeping antibody) and the clinical pipeline status for MMN, delayed graft function, and dermatomyositis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a9ac-701c-b608-a7d685a23a86/14",
  "deckHref": "/decks/019de074-a9ac-701c-b608-a7d685a23a86",
  "deckJsonHref": "/decks/019de074-a9ac-701c-b608-a7d685a23a86.json",
  "deckAnchorHref": "/decks/019de074-a9ac-701c-b608-a7d685a23a86#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.28,
        "w": 0.15,
        "x": 0.83,
        "y": 0.01
      },
      "kind": "callout",
      "text": "clinical Broaden immunology pipeline",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0817c968-3e16-411d-827b-98fb53e9b4e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "image",
      "text": "Diagram of a sweeping antibody showing pH/Ca2+ switch, optimal recycling, and no effector function.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03eeb1e2-46a7-47ae-a2a9-97fe4da5d910",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "Indication selection starts with autoimmune diseases driven by classical and/or lectin pathway. Phase 2 proof-of-concept trial underway in multifocal motor neuropathy (MMN) with interim data expected in mid-2023. Phase 2 trials to start in delayed graft function and dermatomyositis.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "220fa1e7-9b92-41cf-bd29-b1c5593a2d73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.45,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "ARGX-117: Targets C2 at Junction of Classical and Lectin Pathways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f6e33e3-b6e2-45cc-8a47-6e7ea7de6314",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 7,
      "beatId": "5f17aabc-eb4c-4e3b-b30e-070b7656292a",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "How",
      "beatSlug": "golden-circle-how",
      "evidence": "The presentation finally explains 'how' (pipeline and growth potential)",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "9faf6166-e0e0-46b6-9e29-f48774efbe4d",
      "evidence": "The presentation uses a golden circle framework to explain the company's mission and growth potential",
      "position": 0,
      "objective": "Explain the company's mission and growth potential",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}